Drug intelligence / Profile preview

SDL-002

Development stage: Preclinical
Lead developer: Synthetic Design Lab
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SDL-002 is a preclinical-stage antibody-drug conjugate (ADC) under development by Synthetic Design Lab. The asset is being investigated for the treatment of Non-Hodgkin Lymphoma (NHL) and various autoimmune disorders. As of 2024, the specific molecular target and the nature of the cytotoxic or immunomodulatory payload remain undisclosed by the developer. The program leverages Synthetic Design Lab's proprietary platform for the engineering of optimized biologic therapies to address B-cell mediated malignancies and immune-mediated inflammatory diseases.

Beyond the preview

Go deeper on SDL-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDL-002.

Explore the full profile